Skip to main content
. 2019 Oct 8;11(10):1505. doi: 10.3390/cancers11101505

Table 2.

Choice of radionuclide imaging based on the underlying germline/somatic mutations and disease characteristics, modified from Taieb et al. [64].

Radionuclide Imaging Method for Diagnosis, Staging, and Follow-Up (Sporadic) PGL, Multifocal/Metastatic Disease, SDHx (Sporadic) PCC (Except SDHx): VHL, EPAS1 (HIF2A), FH, PHD1/2, Kinase Signaling-Associated (NF1, RET, MAX)
First choice [68Ga]Ga-DOTA-SSA PET/CT
reveals the predictive power for efficacy of PRRT		 [18F]FDOPA PET/CT
Second choice [18F]FDG PET/CT
for SDHx-related PGL
(except for SDHD-related HN PGL)		 [68Ga]Ga-DOTA-SSA PET/CT
(except for EPAS1 (HIF2A), PHD1/2)
Second choice [18F]FDOPA PET/CT
for SDHD-related HN PGL		 [18F]FDG PET/CT
for EPAS1/2 (HIF2A), PHD1/2